- Previous Close
11.08 - Open
11.14 - Bid 10.83 x 100
- Ask 10.89 x 100
- Day's Range
10.64 - 11.35 - 52 Week Range
9.80 - 17.82 - Volume
771,741 - Avg. Volume
599,390 - Market Cap (intraday)
688.305M - Beta (5Y Monthly) 1.32
- PE Ratio (TTM)
-- - EPS (TTM)
-0.91 - Earnings Date Mar 5, 2025 - Mar 10, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.43
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
www.evolus.com322
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: EOLS
View MorePerformance Overview: EOLS
Trailing total returns as of 12/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EOLS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EOLS
View MoreValuation Measures
Market Cap
688.30M
Enterprise Value
733.14M
Trailing P/E
--
Forward P/E
83.33
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.65
Price/Book (mrq)
116.86
Enterprise Value/Revenue
2.95
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-22.33%
Return on Assets (ttm)
-9.93%
Return on Equity (ttm)
--
Revenue (ttm)
248.33M
Net Income Avi to Common (ttm)
-55.46M
Diluted EPS (ttm)
-0.91
Balance Sheet and Cash Flow
Total Cash (mrq)
85.03M
Total Debt/Equity (mrq)
2,205.01%
Levered Free Cash Flow (ttm)
-7.4M